PRMT4 inhibitor
/ BMS, Ipsen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 14, 2022
Characterization of CARM1 Inhibition in Skeletal Muscle.
(PubMed, FASEB J)
- "Mice were treated with either a CARM1 inhibitor (150 mg/kg EZM2302; Epizyme, Inc.) or vehicle via oral gavage BID for 2, 4, or 8 days. Furthermore, CARM1 inhibitor treatment may affect muscle performance with males being more sensitive to the functional outcomes of CARM1 suppression than females. Future work in our laboratory will examine the mechanisms and functional consequences of sex-based differences in CARM1 biology within skeletal muscle."
Journal • PABPC1
1 to 1
Of
1
Go to page
1